The Valley of Death in anticancer drug development: a reassessment
about
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-ImagingMouse models of human disease: An evolutionary perspectiveMarine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Parallel universes of Black Six biology.The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells.A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput formatPrecision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.NIH TRND program: successes in preclinical therapeutic development.Does age matter? The impact of rodent age on study outcomesEconomic and societal dimensions of nanotechnology-enabled drug delivery.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.Ex vivo culture of human prostate tissue and drug development.Nanoparticles targeting mechanisms in cancer therapy: current limitations and emerging solutions.Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature.An efficient injectable formulation with block copolymer micelles for hydrophobic antitumor candidate-pyridazinone derivatives.A Multilayered Cell Culture Model for Transport Study in Solid Tumors: Evaluation of Tissue Penetration of Polyethyleneimine Based Cationic Micelles.Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer.Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial.Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants.Tropism of the in situ growth from biopsies of childhood neuroectodermal tumors following transplantation into experimental teratoma.Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
P2860
Q28553420-9AF847BE-F52B-4204-AEFA-52A06EC23457Q28602393-3E41FCC1-1182-4A07-99E2-F97338B591E7Q33834080-708BDFAB-6422-4A0A-A3F6-AB0D4D03D483Q33941001-8257EEA5-37BD-4371-8A62-2D1B42B48FB9Q35205032-5086C8BB-280C-4A7B-B4D6-E87AAB62CEC5Q35817502-E4F78281-1B4B-4189-BE9D-033F68BE64E2Q36288987-3B8A11C8-FFC7-463B-A263-913B9A176BDCQ37270283-8799FAEF-7A03-4993-B471-C44872B09C9AQ37722647-B2ADBE5D-11B8-4FB8-B939-C1E4C1B1DAD6Q38081220-21995894-8185-47CF-815A-F9D68740AC4CQ38097867-23F9D01B-48FA-4951-A001-765FDCF04E1BQ38113460-5C608048-4DA2-4A9E-B8BE-028B61C096EFQ38136246-BD2A7D00-A8CF-49F3-8494-97019F9F877EQ38351132-E23D2367-C5EC-49F3-A2D1-CC8349C6F53FQ38848926-EE499B31-12FE-4572-BE43-628F7A06CF6DQ39313613-4F1991DA-0D36-48A4-B365-63FB41C02736Q45070681-077249D8-947F-4B9F-BFDC-886AAB996E46Q47115739-4BAA8B2F-7D1D-409E-9154-83E131864172Q48319014-B4D54B98-17E5-4A4E-ADFC-8216E191F4BFQ52327617-2F51790E-A68D-4B55-A1C3-0A66191BCA43Q55461443-39E3288E-8EFE-4CDE-A311-78BCD75D5A2DQ58699214-0A8B9B6A-2A5D-4A78-9C19-DE0BAC5D851D
P2860
The Valley of Death in anticancer drug development: a reassessment
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The Valley of Death in anticancer drug development: a reassessment
@ast
The Valley of Death in anticancer drug development: a reassessment
@en
The Valley of Death in anticancer drug development: a reassessment
@nl
type
label
The Valley of Death in anticancer drug development: a reassessment
@ast
The Valley of Death in anticancer drug development: a reassessment
@en
The Valley of Death in anticancer drug development: a reassessment
@nl
prefLabel
The Valley of Death in anticancer drug development: a reassessment
@ast
The Valley of Death in anticancer drug development: a reassessment
@en
The Valley of Death in anticancer drug development: a reassessment
@nl
P2860
P3181
P1476
The Valley of Death in anticancer drug development: a reassessment
@en
P2093
David J. Adams
P2860
P304
P3181
P356
10.1016/J.TIPS.2012.02.001
P407
P577
2012-04-01T00:00:00Z